Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity?

Hepatitis C virus (HCV) has been associated with the development of B-cell non-Hodgkin lymphomas. We recently reported the regression of splenic lymphoma with villous lymphocytes (SLVL) in patients with HCV after antiviral treatment, demonstrating a direct role of HCV in lymphomagenesis. This study...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2005-01, Vol.105 (1), p.74-76
Main Authors: Saadoun, David, Suarez, Felipe, Lefrere, François, Valensi, Françoise, Mariette, Xavier, Aouba, Achille, Besson, Caroline, Varet, Bruno, Troussard, Xavier, Cacoub, Patrice, Hermine, Oliver
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cryoglobulinemia - complications
Cryoglobulinemia - drug therapy
Cryoglobulinemia - virology
Female
Hematologic and hematopoietic diseases
Hepacivirus - genetics
Hepacivirus - physiology
Hepatitis C - complications
Hepatitis C - drug therapy
Hepatitis C - virology
Human viral diseases
Humans
Infectious diseases
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphocytes - pathology
Lymphoma - complications
Lymphoma - drug therapy
Lymphoma - pathology
Lymphoma - virology
Male
Medical sciences
Middle Aged
Splenic Neoplasms - complications
Splenic Neoplasms - drug therapy
Splenic Neoplasms - pathology
Splenic Neoplasms - virology
Treatment Outcome
Viral diseases
Viral hepatitis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hepatitis C virus (HCV) has been associated with the development of B-cell non-Hodgkin lymphomas. We recently reported the regression of splenic lymphoma with villous lymphocytes (SLVL) in patients with HCV after antiviral treatment, demonstrating a direct role of HCV in lymphomagenesis. This study expands our previous results in 18 patients with chronic HCV and SLVL. Mixed cryoglobulinemia (MC) was present in all cases and was symptomatic in 13 (72%). All patients were treated with interferon alone or in association with ribavirin. Hematologic and virologic responses were correlated. Fourteen (78%) patients achieved a sustained complete hematologic response after clearance of HCV RNA. Two patients had a virologic partial response and achieved a complete hematologic response. Two virologic nonresponders achieved partial hematologic response. Regardless of the response, monoclonal immunoglobulin gene rearrangement persisted after treatment. This study underscores the role of HCV in the lymphomagenesis and the benefit of antiviral treatment for patients presenting with HCV-driven lymphoproliferations.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2004-05-1711